Jnana Therapeutics

View the org chart displaying its 22 main executives

Most searched biographies at Jnana Therapeutics

• Joanne Kotz, Director, President and Chief Executive Officer
• Annie Chen, Director
• Stuart Schreiber, Director

Popular executive movements at Jnana Therapeutics

• George Vratsanos has joined the company as Chief Medical Officer and Head of R&D  (posted on July 20 2023).

Create your alert
to follow the executive moves at Jnana Therapeutics.

Jnana Therapeutics has 2,276 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Bruker has announced the acquisition of NanoString Technologies  (posted on April 18 2024).
• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (posted on April 16 2024).
• Nurix Therapeutics has just announced a $175 Million fundraising (posted on April 13 2024).

Popular contacts in Biotechnology

• Vik Bajaj - Director at Interline Therapeutics
• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by Jnana Therapeutics

• News & Insights | Jnana Therapeutics
• Jnana Therapeutics to Present Preclinical Data for its PKU Program at the 2022 National PKU Alliance (NPKUA) Conference • Jnana Therapeutics
• Jnana Therapeutics Announces Appointment of Doug Pagán, MBA, as Chief Financial Officer and Chief Operating Officer • Jnana Therapeutics
• Jnana Therapeutics Announces Promotion of Joel Barrish, Ph.D., to President and Chief Scientific Officer • Jnana Therapeutics
• Jnana Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference • Jnana Therapeutics
• Jnana Therapeutics Announces Appointment of John Throup, Ph.D. as Senior Vice President, Head of Development • Jnana Therapeutics
• Jnana Therapeutics to Advance JNT-517 as Development Candidate and Potential First-in-Class Oral Treatment for PKU • Jnana Therapeutics
• Jnana Therapeutics closes $50 million Series B financing to advance lead PKU program and small molecule pipeline based on next gen chemoproteomic platform • Jnana Therapeutics
• Jnana Therapeutics Expands Leadership Team with Two Experienced Biopharmaceutical Executives • Jnana Therapeutics
• Jnana Therapeutics Appoints Dr. Annie Chen to Board of Directors and Dr. Katalin Susztak to Scientific Advisory Board • Jnana Therapeutics
• View more press releases Close

Social media about Jnana Therapeutics

• Jnana Therapeutics on Wikipedia, Google News & Yahoo Finance
• Jnana Therapeutics on LinkedIn, Twitter & YouTube

Contact by email its executives including Joanne Kotz

Call Jnana Therapeutics at +1 857...

View the org chart

Register to receive your alert

Report an error